Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$16.8 million.

  • Spyre Therapeutics' Net Cash Flow fell 16422.47% to -$16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year increase of 6723.18%. This contributed to the annual value of -$99.8 million for FY2024, which is 16531.81% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Net Cash Flow of -$16.8 million as of Q3 2025, which was down 16422.47% from $33.2 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Net Cash Flow registered a high of $200.1 million during Q2 2023, and its lowest value of -$182.4 million during Q2 2024.
  • For the 5-year period, Spyre Therapeutics' Net Cash Flow averaged around -$1.4 million, with its median value being -$492000.0 (2022).
  • As far as peak fluctuations go, Spyre Therapeutics' Net Cash Flow plummeted by 1122674.87% in 2023, and later soared by 3058253.97% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Net Cash Flow (Quarter) stood at -$9.5 million in 2021, then soared by 56.45% to -$4.1 million in 2022, then surged by 2445.66% to $97.3 million in 2023, then plummeted by 81.65% to $17.9 million in 2024, then plummeted by 193.86% to -$16.8 million in 2025.
  • Its last three reported values are -$16.8 million in Q3 2025, $33.2 million for Q2 2025, and -$40.9 million during Q1 2025.